NCT06930651View on ClinicalTrials.gov

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 3, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2030

Conditions
Myeloid Malignancies
Interventions
DRUG

Dexamethasone

Given Orally

DRUG

Cyclophosphamide

Given by IV

DRUG

Fludarabine

Given by IV

DRUG

Decitabine

Given by IV

BIOLOGICAL

TGFBR2 KO CAR27/IL-15 NK cells

Given by Infusion

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT06930651 - A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies | Biotech Hunter | Biotech Hunter